Clinical Trial Goal
To find out:
- The highest dose of epcoritamab and ibrutinib that's safe to give
- If the combination of epcoritamab and ibrutinib is safe and works well to treat B-NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have B-cell NHL. Some examples include:
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- High-grade B-cell lymphoma
- Primary Mediastinal large B-cell lymphoma (PMBCL)
- Have cancer cells with marker CD20 (CD20+)
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with a bispecific antibody that targets CD3 and CD20. Your doctor can tell you this
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Have not had autologous (your own cells) BMT in the last 3 months
- Have not had CAR T cell therapy in the last 1 month
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Epcoritamab is a bispecific monoclonal antibody that targets CD3 and CD20 on certain cells.
Ibrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Ibrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Epcoritamab – Given as a shot under your skin 1 time each week
- Ibrutinib – A pill that you take by mouth 1 time each day
You may continue treatment for up to 1 year. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved epcoritamab to treat DLBCL and ibrutinib to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Using them in this way to treat B-NHL that has relapsed or is refractory is new and unproven.
Contacts
The Ohio State University Comprehensive Cancer Center, 800-293-5066, OSUCCCClinicaltrials@osumc.edu
Locations
University of Minnesota/Masonic Cancer CenterNOT_YET_RECRUITING
Minneapolis, Minnesota
Marie Hu, 612-624-6715, hu000322@umn.edu
Ohio State University Comprehensive Cancer CenterRECRUITING
Columbus, Ohio
Yazeed Sawalha, 614-293-0837, Yazeed.sawalha@osumc.edu
Sponsors
collaborator: AbbVie, collaborator: Genmab, lead: Yazeed Sawalha
